Publications by authors named "Jane M Hook"

5Publications

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

J Clin Oncol 2015 Jul 1;33(20):2279-87. Epub 2015 Jun 1.

Stefan S. Bielack, Klinikum Stuttgart-Olgahospital, Stuttgart; Mathias Werner, Helios Klinikum Emil von Behring; Per-Ulf Tunn, Helios Klinikum Berlin-Buch, Berlin; Knut Helmke, Altonaer Kinderkrankenhaus, Hamburg; Heribert Jürgens, Gabriele Calaminus, Joachim Gerss, and Trude Butterfass-Bahloul, Universitätsklinikum Münster, Münster; Peter Reichardt, Klinik für Interdisziplinäre Onkologie, Bad Saarow, Germany; Sigbjørn Smeland and Kirsten Sundby Hall, Oslo University Hospital; Kirsten Sundby Hall, Norwegian Radium Hospital, Oslo, Norway; Jeremy S. Whelan, University College London Hospitals; Gordana Jovic, Jane M. Hook, and Matthew R. Sydes, University College London; Beatrice Seddon and Maria Michelagnoli, University College Hospital, London; Bernadette Brennan, Christie Hospital and Royal Manchester Children's Hospital, Manchester; Susan Picton, Leeds University Hospital, Leeds, United Kingdom; Neyssa Marina, Stanford University Medical Center; Claudia Deffenbaugh, Lucille Salter Packard Children's Hospital, Palo Alto; Mark D. Krailo, Children's Oncology Group, Arcadia, CA; Mark Gebhardt and Allen Goorin, Dana-Farber Cancer Institute; Mark Gebhardt and Lisa A. Teot, Children's Hospital Boston, Boston, MA; Zsuzsanna Pápai, National Medical Center, Budapest, Hungary; James Meyer, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA; Helen Nadel, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia; Mark Bernstein, Dalhousie University, Halifax, Nova Scotia, Canada; R. Lor Randall, University of Utah, Salt Lake City, UT; Rajaram Nagarajan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; G. Douglas Letson, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL; Daniel Baumhoer, Universitätsspital Basel; Thomas Kühne, University Children's Hospital Basel, Basel, Switzerland; Leo Kager, St Anna's Children Hospital; Reinhard Windhager, Medica

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345PMC
July 2015

Maintenance therapy in ovarian cancer.

Curr Opin Oncol 2014 Sep;26(5):521-8

aUCL Hospitals bMedical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London (UCL) cUCL Cancer Institute and UCL Hospitals, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000110DOI Listing
September 2014

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.

Cancer Treat Rev 2012 Oct 29;38(6):662-72. Epub 2011 Dec 29.

UCL Cancer Institute, University College London, London W1T 4TJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.11.009DOI Listing
October 2012